Biogen Inc
BIIB201.180USD
+15.820+8.53%
終値 02/06, 16:00（ET）15分遅れの株価
29.53B時価総額
22.80直近12ヶ月PER
詳細情報 Biogen Inc 企業名
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Biogen Incの企業情報
企業コードBIIB
会社名Biogen Inc
上場日Sep 17, 1991
最高経営責任者「CEO」Viehbacher (Christopher A)
従業員数7605
証券種類Ordinary Share
決算期末Sep 17
本社所在地225 Binney Street
都市CAMBRIDGE
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号02142
電話番号17814642000
ウェブサイトhttps://www.biogen.com/
企業コードBIIB
上場日Sep 17, 1991
最高経営責任者「CEO」Viehbacher (Christopher A)
Biogen Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
56.35K
+20082.00%
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
29.22K
+3160.00%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
17.50K
+3921.00%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
14.22K
+167.00%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.35K
+2370.00%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
11.23K
-2223.00%
Mr. Jesus B. Mantas
Mr. Jesus B. Mantas
Independent Director
Independent Director
8.42K
+2370.00%
Ms. Priya Singhal, M.D.
Ms. Priya Singhal, M.D.
Executive Vice President, Head of Development
Executive Vice President, Head of Development
6.27K
-748.00%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
5.47K
+2370.00%
Ms. Susan Langer
Ms. Susan Langer
Independent Director
Independent Director
3.79K
+2370.00%
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
56.35K
+20082.00%
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
29.22K
+3160.00%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
17.50K
+3921.00%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
14.22K
+167.00%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.35K
+2370.00%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
11.23K
-2223.00%
収益内訳
通貨: USD更新時刻: Tue, Jan 6
通貨: USD更新時刻: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
MS product revenues-TYSABRI
827.20M
32.64%
Spinal Muscular Atrophy-SPINRAZA
533.30M
21.04%
MS product revenues-Fumarate
382.80M
15.10%
MS product revenues-Interferon
246.90M
9.74%
Biosimilar product revenues-BENEPALI
121.90M
4.81%
他の
422.60M
16.67%
地域別USD
会社名
収益
比率
United States
1.37B
54.18%
Rest of world
911.60M
35.96%
United states-Revenues from anti-CD20 therapeutic
493.90M
19.49%
Rest of World-Other revenues
151.20M
5.97%
事業別
地域別
事業別USD
会社名
収益
比率
MS product revenues-TYSABRI
827.20M
32.64%
Spinal Muscular Atrophy-SPINRAZA
533.30M
21.04%
MS product revenues-Fumarate
382.80M
15.10%
MS product revenues-Interferon
246.90M
9.74%
Biosimilar product revenues-BENEPALI
121.90M
4.81%
他の
422.60M
16.67%
株主
更新時刻: Sun, Jan 4
更新時刻: Sun, Jan 4
株主統計
種類
株主統計
株主統計
比率
The Vanguard Group, Inc.
11.83%
PRIMECAP Management Company
10.19%
BlackRock Institutional Trust Company, N.A.
5.60%
State Street Investment Management (US)
4.99%
Wellington Management Company, LLP
2.89%
他の
64.50%
株主統計
株主統計
比率
The Vanguard Group, Inc.
11.83%
PRIMECAP Management Company
10.19%
BlackRock Institutional Trust Company, N.A.
5.60%
State Street Investment Management (US)
4.99%
Wellington Management Company, LLP
2.89%
他の
64.50%
種類
株主統計
比率
Investment Advisor
50.71%
Investment Advisor/Hedge Fund
26.89%
Hedge Fund
8.04%
Pension Fund
2.80%
Research Firm
2.44%
Sovereign Wealth Fund
1.59%
Bank and Trust
1.54%
Individual Investor
0.17%
Family Office
0.16%
他の
5.64%
機関投資家保有株
更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
2068
138.14M
94.13%
-8.38M
2025Q3
2054
139.52M
98.56%
+3.73M
2025Q2
2076
135.78M
99.30%
-133.40K
2025Q1
2125
136.05M
101.20%
-12.08M
2024Q4
2114
138.28M
98.83%
+2.02M
2024Q3
2089
135.94M
98.13%
+100.43K
2024Q2
2100
135.44M
97.85%
-355.51K
2024Q1
2106
135.99M
97.60%
-5.88M
2023Q4
2136
135.17M
94.89%
+4.09M
2023Q3
2150
131.42M
95.94%
-1.80M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
The Vanguard Group, Inc.
17.21M
11.73%
-2.37K
-0.01%
Sep 30, 2025
PRIMECAP Management Company
14.95M
10.19%
-847.42K
-5.36%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
8.21M
5.6%
+19.35K
+0.24%
Sep 30, 2025
State Street Investment Management (US)
7.32M
4.99%
-149.06K
-2.00%
Sep 30, 2025
Wellington Management Company, LLP
4.25M
2.89%
-551.92K
-11.50%
Sep 30, 2025
Geode Capital Management, L.L.C.
4.07M
2.77%
+150.63K
+3.84%
Sep 30, 2025
Point72 Asset Management, L.P.
3.87M
2.64%
+41.17K
+1.07%
Sep 30, 2025
Norges Bank Investment Management (NBIM)
2.26M
1.54%
-61.02K
-2.62%
Jun 30, 2025
Invesco Capital Management LLC
2.13M
1.45%
+90.48K
+4.43%
Sep 30, 2025
BlackRock Asset Management Ireland Limited
1.89M
1.29%
+95.29K
+5.32%
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
Invesco Biotechnology & Genome ETF
5.49%
First Trust NASDAQ Pharmaceuticals ETF
4.45%
iShares Neuroscience and Healthcare ETF
4.25%
First Trust NYSE Arca Biotechnology Index Fund
3.53%
VanEck Biotech ETF
3.46%
Invesco Pharmaceuticals ETF
3.01%
iShares Health Innovation Active ETF
2.81%
First Trust Health Care Alphadex Fund
2.4%
ProShares Ultra Nasdaq Biotechnology
2.22%
Alger Russell Innovation ETF
2.21%
詳細を見る
Invesco Biotechnology & Genome ETF
比率5.49%
First Trust NASDAQ Pharmaceuticals ETF
比率4.45%
iShares Neuroscience and Healthcare ETF
比率4.25%
First Trust NYSE Arca Biotechnology Index Fund
比率3.53%
VanEck Biotech ETF
比率3.46%
Invesco Pharmaceuticals ETF
比率3.01%
iShares Health Innovation Active ETF
比率2.81%
First Trust Health Care Alphadex Fund
比率2.4%
ProShares Ultra Nasdaq Biotechnology
比率2.22%
Alger Russell Innovation ETF
比率2.21%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
